Status: Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Participants needed: 2,500
Trial details
Phase: Phase 3Age: 65+Biological sex: AllType: InterventionalSponsor: Anthos Therapeutics, Inc.Updated: Jul 13, 2026Locations: 789
Eligibility criteria
Patient is able to understand and has provided written informed consent to parti... [+5]
AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary em... [+5]